Talha Badar
@talhabadarmd.bsky.social
Hematologist-Oncologist at Mayo Clinic. Interest in Acute Leukemia and Myeloid disorders.
#weekend_review Venetoclax in ALL: an evolving story VEN combinations are showing encouraging activity across frontline Ph− ALL and R/R B- and T-ALL BH3 profiling offers a functional way to interrogate these dependencies—but remains investigational in ALL Visual summary 👇 #ALL #Leukemia
Relapsed or Resistant Chronic-Phase Chronic Myeloid Leukemia Treatment from @talhabadarmd.bsky.social: myopenmedicine.com/algorithms/r...
Relapsed or Resistant Chronic-Phase Chronic Myeloid Leukemia Treatment
The algorithm is broadly aligned with current chronic-phase CML guidance: confirm an unfavorable molecular trajectory, exclude reversible causes, perform mutation testing, and select subsequent therap...
myopenmedicine.com
Is the chemo-free era here for Ph+ ALL? ALL2820: ponatinib + blinatumomab vs imatinib + chemo: 📈 24-mo EFS 86% vs 67% 🧬 Molecular response 71% vs 49% 📉 Relapse 5% vs 13% 🎯 HSCT in CR1 19% Randomized Ph III evidence of a paradigm shift. #PhPositiveALL #Leukemia
Talha Badar@talhabadarmd.bsky.social · 3w agoNEJM: ponatinib + blinatumomab (chemo-free) beat imatinib + chemo in Ph+ ALL. 236 adults, randomized 2:1. 24-mo EFS 86% vs 67% (P<0.001); grade ≥3 AEs 34% vs 47%. Caveats: open-label, median follow-up 23.7 mo. doi.org/10.1056/NEJMoa2606208 #leusm #ALL
NEJM: ponatinib + blinatumomab (chemo-free) beat imatinib + chemo in Ph+ ALL. 236 adults, randomized 2:1. 24-mo EFS 86% vs 67% (P<0.001); grade ≥3 AEs 34% vs 47%. Caveats: open-label, median follow-up 23.7 mo. doi.org/10.1056/NEJMoa2606208 #leusm #ALL
This weekend our Mayo Clinic leukemia group joined the comprehensive leukemia course in Las Vegas, where I spoke on chemotherapy-sparing approaches in B-ALL: immunotherapy, TKIs, and MRD-guided sequencing. @mayocliniccancer.bsky.social
Should we transplant #TP53-mutated MDS? Outcomes are poor, but poor ≠ futile. Selected patients can achieve durable survival after alloHCT. TP53 should trigger refinement, not automatic exclusion. Select carefully. Transplant deliberately. Prevent relapse aggressively.👇🏽
Newly Diagnosed Non-APL Acute Myeloid Leukemia: Initial Treatment Selection from @talhabadarmd.bsky.social: myopenmedicine.com/algorithms/n...
Newly Diagnosed Non-APL Acute Myeloid Leukemia: Initial Treatment Selection
This algorithm is broadly aligned with contemporary adult non-APL AML practice: urgent exclusion of APL and stabilization, early comprehensive cytogenetic/molecular profiling, fitness-based selection ...
myopenmedicine.com
🧠 CNS prophylaxis remains essential in ALL, especially as therapy becomes chemo-attenuated or chemo-free. Blinatumomab/inotuzumab do not replace CNS-directed therapy. Modern regimens often use 12–15 IT treatments, tailored to regimen and risk. #ALL #Leukemia #Hematology
#weekend_review #mdssm HIGHER-RISK #MDS: A DECADE OF CLINICAL TRIALS The last decade in HR-MDS has taught us a humbling lesson Promising biology ≠ successful phase III trial. Higher response rate ≠ longer survival. why so many failed, and where we go next. 👇
Exciting #DELPHINUS results: Dara + chemo achieved 83% ORR, with 75% proceeding to allo-HSCT and 24-month OS of 41% in R/R T-ALL. As EA9213 co-chair, excited to see whether Dara can eradicate MRD and deepen remission in T-ALL. #TcellALL #Leusm doi.org/10.1182/bloo...
Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study
Key PointsDaratumumab plus chemotherapy may effectively bridge children and young adults with relapsed/refractory T-cell ALL/LL to HSCT.No new safety conce
doi.org
@bloodjournal.bsky.social study evaluated using leukemia cell lines Ziftomenib ⬇️ MEIS1/HOXA signaling, induced differentiation, and caused leukemia regression in NPM1/KMT2Ar CRISPR-engineered MEN1-mt models showed activity > T349M & G331R—but resistance> M327I/G331D. #AML doi.org/10.1182/bloo...
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
Key PointsZiftomenib shows pronounced preclinical activity in the menin-KMT2A–dependent leukemia models, including patient-derived xenografts.Ziftomenib de
doi.org
Newly Diagnosed Philadelphia Chromosome–Positive ALL: Frontline TKI Selection, Early Blinatumomab, MRD, and Allo-HCT Decision-Making algorithm from @talhabadarmd.bsky.social: myopenmedicine.com/algorithms/n...
Newly Diagnosed Philadelphia Chromosome–Positive ALL:Frontline TKI Selection, Early Blinatumomab, MRD, and Allo-HCT Decision-Making
myopenmedicine.com
On call and need a quick refresher on newly diagnosed #Ph+ #ALL? I created a practical, evidence-based clinical algorithm covering: • Frontline TKI selection • Early blinatumomab integration • MRD-guided decision making • When to consider allo-HCT myopenmedicine.com/algorithms/n...
Newly Diagnosed Philadelphia Chromosome–Positive ALL:Frontline TKI Selection, Early Blinatumomab, MRD, and Allo-HCT Decision-Making
myopenmedicine.com
@VuMedi talk on our COMMAND Consortium study in Ph+ ALL. Early CMR (3 months) identifies patients with excellent outcomes. AlloHCT reduced relapse but did not improve OS, supporting a more individualized, MRD-guided transplant strategy. #Leukemia #PhALL #HemOnc www.vumedi.com/video/predic...
Predictors of Complete Molecular Response and AlloHSCT Outcomes in Philadelphia Chromosome–Positive ALL: The COMMAND Study
A video from Talha Badar, posted on Jul 14, 2026.
vumedi.com
Leukemia and Myeloid Diseases: Highlights of 2025 - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/talha... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Leukemia #MyeloidDiseases
Talha Badar: Leukemia and Myeloid Diseases - Highlights of 2025 - OncoDaily
Talha Badar: Leukemia and Myeloid Diseases - Highlights of 2025 / cancer, Leukemia, Myeloid Diseases, OncoDaily, Oncology, Talha Badar
oncodaily.com
check out this paper in @bloodjournals.hematology.org led by @talhabadarmd.bsky.social on PPM1D in CHIP/CCUS! Glad to contribute to this effort pubmed.ncbi.nlm.nih.gov/41499760/
From Germline to Donor-Derived Mutations in MN - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/talha... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Talha Badar: From Germline to Donor-Derived Mutations in MN - OncoDaily
Talha Badar: From Germline to Donor-Derived Mutations in MN / Blood Global Hematology, cancer, OncoDaily, Oncology, Talha Badar
oncodaily.com
excited to be a part of this effort looking at the impact of CMR on survival outcomes in Ph+ ALL led by @talhabadarmd.bsky.social! www.tandfonline.com/doi/full/10....
Submissions Open for Special Issue on Evolving Paradigms in Acute Myeloid Leukemia - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/talha... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Talha Badar: Submissions Open for Special Issue on Evolving Paradigms in Acute Myeloid Leukemia - OncoDaily
Talha Badar: Submissions Open for Special Issue on Evolving Paradigms in Acute Myeloid Leukemia / AML, cancer, OncoDaily, Oncology, Talha Badar
oncodaily.com
Newly Diagnosed Non-APL Acute Myeloid Leukemia: Initial Treatment Selection from @talhabadarmd.bsky.social: myopenmedicine.com/algorithms/n...
Newly Diagnosed Non-APL Acute Myeloid Leukemia: Initial Treatment Selection
This algorithm is broadly aligned with contemporary adult non-APL AML practice: urgent exclusion of APL and stabilization, early comprehensive cytogenetic/molecular profiling, fitness-based selection ...
myopenmedicine.com
Exciting News for Our Leukemia Patients - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/talha... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Talha Badar: Exciting News for Our Leukemia Patients - OncoDaily
Talha Badar: Exciting News for Our Leukemia Patients / Adolfo de la Fuente Burguera, Amir T. Fathi, Amitava Mitra, Arnaud Pigneux, cancer, Celine Berthon,
oncodaily.com
Key Abstracts to Watch in ALL at ASH 2025 - Talha Badar @talhabadarmd.bsky.social @ash.hematology.org oncodaily.com/voices/talha... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ALL #ASH25
Talha Badar: Key Abstracts to Watch in ALL at ASH 2025 - OncoDaily
Talha Badar: Key Abstracts to Watch in ALL at ASH 2025 / Acute Lymphoblastic Leukemia, ALL, ASH, ASH 2025, ASH25, cancer, Headlines, OncoDaily, Oncology,
oncodaily.com
Key Abstracts to Watch in MDS/CMML at ASH 2025 - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/talha... #ASH2025 #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Talha Badar: Key Abstracts to Watch in MDS/CMML at ASH 2025 - OncoDaily
Talha Badar: Key Abstracts to Watch in MDS/CMML at ASH 2025 / ASH 2025, ASH25, cancer, OncoDaily, Oncology, Talha Badar
oncodaily.com
Promising cCR Rates in VICEROY Phase 1/2 FLT3m AML Study - Talha Badar @talhabadarmd.bsky.social oncodaily.com/voices/425957 #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Talha Badar: Promising cCR Rates in VICEROY Phase 1/2 FLT3m AML Study - OncoDaily
Talha Badar: Promising cCR Rates in VICEROY Phase 1/2 FLT3m AML Study / cancer, Jessica Altman, OncoDaily, Oncology, Talha Badar
oncodaily.com
Inside ASH25 with Talha Badar @ash.hematology.org @talhabadarmd.bsky.social oncodaily.com/voices/ash25... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASH #ASH25 #ASH2025
Inside ASH25 with Talha Badar - OncoDaily
Inside ASH25 with Talha Badar / ASH, ASH 2025, ASH25, cancer, Headlines, OncoDaily, Oncology, Talha Badar
oncodaily.com
👇🏽 Trial finding that led to approval: Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation. 📈 Led to FDA approval (2025) for R/R NPM1m AML. #AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…
AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽
AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽
